![Merja Haikola](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Merja Haikola is currently the Accountable Director at BBS-Bioactive Bone Substitutes Plc since 2023.
Previously, she worked as a Principal at AKELA Pharma Oy from 1988 to 2003, at Leiras Oy as a Principal, and at Cancer Targeting Technologies Oy as a Principal from 2003 to 2006.
| Unternehmen | Position | Beginn |
|---|---|---|
| BBS-BIOACTIVE BONE SUBSTITUTES OYJ | Comptroller/Controller/Auditor | 23.12.2023 |
| Unternehmen | Position | Ende |
|---|---|---|
Cancer Targeting Technologies Oy
 Cancer Targeting Technologies Oy Pharmaceuticals: MajorHealth Technology Develops anticancer drugs and drug delivery systems | Corporate Officer/Principal | 01.01.2006 |
AKELA Pharma Oy
 AKELA Pharma Oy Pharmaceuticals: OtherHealth Technology Develops inhalers, inhalation products, and related production technology | Corporate Officer/Principal | 01.01.2003 |
Leiras Oy
 Leiras Oy Pharmaceuticals: MajorHealth Technology Develops pharmaceutical solutions | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
AKELA Pharma Oy
AKELA Pharma Oy Pharmaceuticals: OtherHealth Technology Develops inhalers, inhalation products, and related production technology | Health Technology |
Leiras Oy
Leiras Oy Pharmaceuticals: MajorHealth Technology Develops pharmaceutical solutions | Health Technology |
Cancer Targeting Technologies Oy
Cancer Targeting Technologies Oy Pharmaceuticals: MajorHealth Technology Develops anticancer drugs and drug delivery systems | Health Technology |
BBS-Bioactive Bone Substitutes Plc
 BBS-Bioactive Bone Substitutes Plc Medical SpecialtiesHealth Technology Develops and manufactures bioactive bone substitute implants | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
